Aromatase inhibitors as first line treatment: Treatment cascade after failure of aromatase inhibitors

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Aromatase; Non steroidal inhibitors; Postmenopause; Steroidal

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT FAILURE; TUMOR; VAGINAL DRYNESS;

EID: 0344441839     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026320907510     Document Type: Conference Paper

References (33)

1. Pasqualini JR, Chetrite GS: The selective estrogen enzyme modulators (SEEM) in breast cancer. In: Pasqualini RJ (ed) Breast Cancer, Prognosis, Treatment and Prevention. Marcel Dekker, Basel, 2002, pp 187-249
2. Wells SA, Santen RT, Lipton A: Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187: 475-484, 1978
3. Brodie AMH: Aromatase inhibitors and their application to the treatment of breast cancer. In: Pasqualini R (ed) Breast Cancer, Prognosis, Treatment and Prevention. Marcel Dekker, Basel, 2002, pp 251-269
4. Buzdar AU, Robertson JFR, Eiermann W, Nabholtz JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors Anastrozole, Letrozole, and Exemestane. Cancer 95(9): 2006-2016, 2002
5. Lonning PE: Overview of aromatase inhibitors and inactivators in the treatment of advanced breast cancer. In: Miller WR, Ingle JN (eds) Endocrine Therapy in Breast Cancer, Marcel Dekker, Basel, 2002, pp 33-46
6. Geisler J, Anker G, Dowsett M, Lonning PE: Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole, Proc ASCO J Clin Oncol 19: 102a, 2000 (abstract 394)
7. Rose C, Vtoraya O, Pluzanska A, Neave F, Clemens M, Chaudri-Ross HA, Wyld P, Lang R: Letrozole (Femara) versus anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc of ASCO J Clin Oncol 21(34a): 2002 (abstract 131)
8. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3): 751-757, 2002
9. Miller WR: Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endo Relat Cancer 65: 187-195, 1999
10. Dixon JM, Grattage L, Renshaw L, Miller WR: Exemestane as neoadjuvant treatment for locally advanced breast cancer: endocrinologic and clinical endpoints. Breast Cancer Res Treat 64: 53, 2000 (abstract 170)
11. The ATAC Trialists' Group: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex" and tamoxifen alone or in combination (ATAC) trial. Br J Cancer 85: 317-324, 2001
12. Dowsett M, Pfister C, Johnson SRD: Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 5: 2338-2343, 1999
13. Hamilton A, Piccart M: The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10: 377-384, 1999
14. Bonneterre J, Thürlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Weebster A, Steinberg M, Von Euler M: Anastrozole versus Tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen and Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18(22): 3748-3757, 2000
15. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, Von Euler M: Anastrozole is superior to Tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18(22): 3758-3767, 2000
16. Bonneterre J, Buzdar A, Nabholtz JMA, Robertson JFR, Thürlimann B, Von Euler M, Sahmoud T, Webster A, Steinberg M: Anastrozole is superior to Tamoxifen as firstline therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9): 2247-2258, 2001
17. Bonneterre J, Nabholtz JM, Buzdar A, Robertson J, Thürlimann B: Anastrozole compared with tamoxifen as firstline therapy for postmenopausal women with advanced breast cancer - Survival analyses. Ann Oncol 13(5): 47, 2002 (abstract 169P)
18. Milla-Santos A, Milla L: Phase III trial of anastrozole (AN) versus tamoxifen (TAM) in postmenopausal (PM) patients (PTS) with hormone-dependant advanced breast cancer (ABC). Eur J Cancer 37(5): 4, 2001 (abstract O-11)
19. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus Tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international Letrozole breast cancer group. J Clin Oncol 19(10): 2596-2606, 2001
20. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Smith R, Chaudri-Ross HA, Lang R, Brady C, Dugan M: Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res Treat 69(3): 211, 2001 (abstract 9)
21. Dirix L, Piccart MJ, Lohrisch C, Beex L, Nooij M, Cameron D: Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (Pts): a European Organisation for the Research and Treatment of Cancer (EORTC breast group). Phase II trial with Pharmacia Upjohn. Proc of ASCO J Clin Oncol 20(29a): 2001 (abstract 114)
22. Thürlimann B, Robertson JFR, Bonneterre J, Buzdar A, Nabholtz JMA: Efficacy of tamoxifen following Arimidex TM (anastrozole) as first-line treatment for advanced breast cancer (ABC) in postmenopausal (PM) women. Breast Cancer Res Treat 64: 51, 2000 (abstract 162)
23. Murray R, Pitt P: Aromatase inhibition with 4-OH Androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35: 249-253, 1995
24. Carlini P, Frassoldati A, Casali A: Formestane (FOR) a steroidal aromatase inhibitor (SAI) after failure of non steroidal aromatase inhibitor (nSAI) (anastrozole: ANZ and letrozole: LTZ): is a clinical benefit still possible? Proceedings of the 25th ESMO congress, Hamburg 13-17 October 2000, Ann Oncol II(Suppl 4): 35, 2000 (abst No 144)
25. Thürlimann B, Paridaens R, Serin D: Third line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing an aminoglutethimide: a phase II multicentre multirational stay. Eur J Cancer 33: 1757-1773, 1997
26. Lonning PE, Bajetta E, Murray R: Activity of exemestane in metastatic breast cancer after failure of non steroidal aromatase inhibitors. A phase 11 trial. J Clin Oncol 18: 2234-2244, 2000
27. Carlini P, Michelotti A, Giannarelli D, Conte PF, Salvadori B, Landucci E, Di Cosimo S, Fabi A, Papaldo P, Cognetti F: Exemestane (EXE) is an effective 3rd line hormonal therapy for postmenopausal metastatic breast cancer (MBC) patients (pts) pretreated with 3rd generation non steroidal aromatase inhibitors (nSAI). Ann Oncol 13(5): 48, 2002 (abstract 171P)
28. Harper-Wynne C, Coombes RC: Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 35: 744-746, 1999
29. Jones S, Vogel C, Arkhipov A: Multicenter phase II trial of exemestane as third line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 17: 3418-3425, 1999
30. Howell A, DeFriend D, Robertson J: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30, 1995
31. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of Fulvestrant versus Anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16): 3386-3395, 2002
32. Perey L, Thürlimann B, Hawle H, Bonnefoi H, Aebi S, Pagani O, Goldhirsch A, Dietrich D: Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors (Ais): An ongoing phase II SAKK trial. Ann Oncol 13(Suppl 5): 48, 2002 (abstract 172P)
33. Carlson RW: Sequencing of endocrine therapies in breast cancer - integration of recent data. Breast Cancer Res Treat 75: S27-S32, 2002